eTable 3 in the Supplement shows the large range of achieved antibody levels after vaccination stratified by cancer diagnosis and treatment type, with especially low levels observed among patients with chronic lymphocytic leukemia and those treated with BTK inhibitors and venetoclax. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.